Exercise capacity, arrhythmic risk profile, and pulmonary function is not influenced by intracoronary injection of Bone Marrow Stem Cells in patients with acute myocardial infarction

2012 ◽  
Vol 159 (2) ◽  
pp. 134-138 ◽  
Author(s):  
Ewa Straburzyńska-Migaj ◽  
Małgorzata Popiel ◽  
Stefan Grajek ◽  
Agnieszka Katarzyńska-Szymańska ◽  
Maciej Lesiak ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Stem Cells ◽  
Bone Marrow ◽  
Pulmonary Function ◽  
Exercise Capacity ◽  
Risk Profile ◽  
Bone Marrow Stem Cells ◽  
Intracoronary Injection

scholarly journals One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133+ Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Samer Mansour ◽  
Denis-Claude Roy ◽  
Vincent Bouchard ◽  
Louis Mathieu Stevens ◽  
Francois Gobeil ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Stem Cells ◽  
Bone Marrow ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Safety Analysis ◽  
Left Ventricular ◽  
Intracoronary Injection ◽  
One Year

Bone marrow stem cell therapy has emerged as a promising approach to improve healing of the infarcted myocardium. Despite initial excitement, recent clinical trials using non-homogenous stem cells preparations showed variable and mixed results. Selected CD133+ hematopoietic stem cells are candidate cells with high potential. Herein, we report the one-year safety analysis on the initial 20 patients enrolled in the COMPARE-AMI trial, the first double-blind randomized controlled trial comparing the safety, efficacy, and functional effect of intracoronary injection of selected CD133+ cells to placebo following acute myocardial infarction with persistent left ventricular dysfunction. At one year, there is no protocol-related complication to report such as death, myocardial infarction, stroke, or sustained ventricular arrhythmia. In addition, the left ventricular ejection fraction significantly improved at four months as compared to baseline and remained significantly higher at one year. These data indicate that in the setting of the COMPARE-AMI trial, the intracoronary injection of selected CD133+ stem cells is secure and feasible in patients with left ventricle dysfunction following acute myocardial infarction.

scholarly journals Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review

2008 ◽  
Vol 29 (15) ◽  
pp. 1807-1818 ◽  
Author(s):  
Enca Martin-Rendon ◽  
Susan J. Brunskill ◽  
Chris J. Hyde ◽  
Simon J. Stanworth ◽  
Anthony Mathur ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Systematic Review ◽  
Acute Myocardial Infarction ◽  
Stem Cells ◽  
Bone Marrow ◽  
Autologous Bone Marrow ◽  
Bone Marrow Stem Cells ◽  
Autologous Bone

Effect of transplantation with autologous bone marrow stem cells on acute myocardial infarction

2013 ◽  
Vol 162 (3) ◽  
pp. 158-165 ◽  
Author(s):  
Chaoquan Peng ◽  
Ke Yang ◽  
Peng Xiang ◽  
Chengxi Zhang ◽  
Liyuan Zou ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Stem Cells ◽  
Bone Marrow ◽  
Autologous Bone Marrow ◽  
Bone Marrow Stem Cells ◽  
Autologous Bone

scholarly journals Impact of Timing following Acute Myocardial Infarction on Efficacy and Safety of Bone Marrow Stem Cells Therapy: A Network Meta-Analysis

2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Bei Liu ◽  
Chong-Yang Duan ◽  
Cheng-Feng Luo ◽  
Cai-Wen Ou ◽  
Zhi-Ye Wu ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Stem Cells ◽  
Bone Marrow ◽  
Meta Analysis ◽  
Bone Marrow Stem Cells ◽  
Left Ventricular Ejection ◽  
Cochrane Library ◽  
Optimal Timing ◽  
Multiple Treatment

Background. The optimal timing for Bone Marrow Stem Cells (BMCs) therapy following acute myocardial infarction (AMI) remains unclear.Aims. To synthesize the evidence from trials using a multiple-treatment comparison method, thereby permitting a broader comparison across multiple timing of BMCs therapy.Methods and Results. Randomized controlled trials in patients with AMI receiving BMCs therapy were identified from PubMed, Ovid LWW, BIOSIS Previews, and the Cochrane Library through January 2015. 2 035 patients of 31 studies included in our analysis were allocated to 5 groups’ treatments: 1~3 days, 4~7 days, 8~14 days, 15~30 days, or placebo/control group. The multiple-treatment meta-analysis showed that 4~7 days’ group could lead to significantly increased left ventricular ejection fraction (LVEF) as compared with control (mean of MDs and 95% CI: 6 months, 3.05 (0.92~5.25); 12 months, 4.18 (2.30~5.84)). Only 4~7 days led to significant reduction of MACEs compared with control (OR and 95% CI 0.34 (0.13~0.96)) for 12-months follow-up. In simulated comparisons, the 4~7 days’ group ranked better than other timing groups for improvement of LVEF or reduction of the incidence of major adverse cardiac events.Conclusions. 4~7 days after AMI might be the optimal timing for cell therapy in terms of efficacy or safety.

Sign in / Sign up

Export Citation Format

Share Document